Plain-English translation of NCT04588285 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether a medication called can help people with early dementia with Lewy bodies — a type of memory loss and thinking problems. Researchers believe this medication may help protect nerve cells in the brain by affecting how the body processes certain proteins. About 180 people in Norway will take either or a placebo (a dummy pill) for 18 months to see if the medication helps with memory, thinking, mood, and daily functioning.
Dementia with Lewy bodies is a serious condition that causes thinking problems, mood changes, and movement difficulties, and there are currently no proven treatments that can slow it down. This medication may work by helping the brain clear harmful proteins, which could potentially slow the disease early on when it may be most effective.
You likely qualify if…
You likely don't qualify if…
You will visit a memory clinic 8 times over 18 months (at screening, week 4, week 8, week 24, week 36, week 52, month 15, and month 18) and receive 16 phone calls to check on your health. You'll start the medication at a low dose and gradually increase it over the first month. Each hospital visit includes thinking tests, mood assessments, blood work, and sometimes brain scans or a spinal tap to measure brain chemicals. After the 18-month blinded phase, all participants are offered to continue taking the medication for one additional year.
AI-generated summary from trial data · Aug 22, 2026 · Not medical advice
Norway